Analyse Ocular Therapeutix, Inc. (OCUL) — Kairos Score 60/100

À propos de Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

9 transactions — 0 achats et 7 ventes déclarés par les dirigeants de Ocular Therapeutix, Inc..

🏦 Hedge Funds

17 fonds institutionnels déclarent une position sur OCUL dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur OCUL.

• Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win
• Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.